menu
    • menu
    [{"orgOrder":0,"company":"OncoArendi Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"OATD-01","moa":"AMCase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"OncoArendi Therapeutics","amount2":0.38,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.38,"dosageForm":"Undisclosed","sponsorNew":"OncoArendi Therapeutics \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"OncoArendi Therapeutics \/ Galapagos"},{"orgOrder":0,"company":"OncoArendi Therapeutics","sponsor":"University of Michigan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"POLAND","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"OncoArendi Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoArendi Therapeutics \/ University of Michigan","highestDevelopmentStatusID":"4","companyTruncated":"OncoArendi Therapeutics \/ University of Michigan"}]

    Find Clinical Drug Pipeline Developments & Deals by OncoArendi Therapeutics

    Menu

    OncoArendi Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OncoArendi Therapeutics

                            Poland arrow
                            ACI Convention
                            Not Confirmed

                            OncoArendi Therapeutics

                            Poland arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : University of Michigan

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan

                            Details : Under the terms of agreement, OncoArendi will confirm certain properties of a series of selective small molecule inhibitors targeting this novel therapeutic target in fibrosis. OncoArendi will then have the option to obtain rights for a worldwide license...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 11, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : University of Michigan

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OncoArendi Therapeutics

                            Poland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            OncoArendi Therapeutics

                            Poland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OATD-01

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Galapagos

                            Deal Size : $380.8 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            OncoArendi and Galapagos Enter Into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis

                            Details : OncoArendi Therapeutics gains global development and commercialization rights of OncoArendi’s OATD-01. OATD-01 is a Phase 2-ready chitotriosidase/acidic mammalian chitinase inhibitor to treat Idiopathic pulmonary fibrosis and other diseases with a fibr...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $29.7 million

                            November 05, 2020

                            Lead Product(s) : OATD-01

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Galapagos

                            Deal Size : $380.8 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth